Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.49 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12437345 | 0.91 | SMYD2 (0.51) | SMYD2SLC5A7HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL12437352 | 0.87 | SLC5A7 (0.49) | SMYD2SLC5A7HRH3MEN1KMT2A | |
| SCHEMBL12437349 | 0.86 | SLC5A7 (0.53) | SMYD2SLC5A7HRH3MEN1KMT2A | |
| SCHEMBL12437957 | 0.86 | SLC5A7 (0.51) | SMYD2SLC5A7MEN1KMT2ADRD2 | |
| SCHEMBL12437354 | 0.86 | DRD2 (0.56) | SMYD2SLC5A7HRH3DRD2DRD3 | |
| SCHEMBL12437336 | 0.84 | SLC5A7 (0.50) | SMYD2SLC5A7MEN1KMT2ADRD2 | |
| SCHEMBL12437347 | 0.83 | SLC5A7 (0.51) | SMYD2SLC5A7HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL12437332 | 0.83 | UTS2R (0.55) | SMYD2SLC5A7MEN1KMT2ALMNA | |
| SCHEMBL12437337 | 0.82 | ALDH1A1 (0.58) | SMYD2SLC5A7MEN1KMT2ARAB9A | |
| SCHEMBL12437331 | 0.82 | SLC5A7 (0.54) | SMYD2SLC5A7HRH3L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | HPGDS, HPGD, DPYD | SMYD2 2555/4885SLC5A7 4329/4885HRH3 788/4885 |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | HPGDS, HPGD, DPYD | SMYD2 2555/4885SLC5A7 4329/4885HRH3 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.